SEC Comment Letter for Sarepta Therapeutics, Inc. (SRPT) (CIK 0000873303) (SRPT) — Apr 16, 2020
Sarepta Therapeutics, Inc. (SRPT) (CIK 0000873303)
Date: April 16, 2020 · CIK: 0000873303 · Accession: 0000000000-20-003288
AI Filing Summary & Sentiment
File numbers found in text: 001-14895
Letter
April 15, 2020 Douglas S. Ingram President and Chief Executive Officer Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, MA 02142 Re:Sarepta Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed April 8, 2020 File No. 001-14895 Dear Mr. Ingram: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Raymond J. Grant, Esq.
Show Raw Text
April 15, 2020
Douglas S. Ingram
President and Chief Executive Officer
Sarepta Therapeutics, Inc.
215 First Street, Suite 415
Cambridge, MA 02142
Re:Sarepta Therapeutics, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed April 8, 2020
File No. 001-14895
Dear Mr. Ingram:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Raymond J. Grant, Esq.